UNSPSC 51191922: Tocofersolan

This classification denotes an antioxidant with the molecular formula C33H54O5(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O03S90U1F2, chemically known as poly(oxy-1,2-ethanediyl), alpha-(4-((3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2h-1-benzopyran-6-yl)oxy)-1,4-dioxobutyl)-omega-hydroxy- but generally known as tocofersolan, which bears US NIH Compound Identifier 71406.

UNSPSC 51191922 Tocofersolan, a Commodity code, reflects state and local procurement of chemical products for facility operations and healthcare supply chains, though the code's nominal scope (a vitamin E derivative) diverges significantly from the actual work being solicited. The City of Meriden recently issued an IFB for sodium bisulfite, a water-treatment chemical unrelated to tocofersolan, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) simultaneously ran an RFP for generic pharmaceuticals and over-the-counter products—also orthogonal to the code's intended scope. State and local governments issue solicitations under this code through municipal utilities, cooperative purchasing alliances, and health-care supply networks. The issuing bodies span city procurement offices and statewide cooperative purchasing vehicles coordinating across multiple member jurisdictions.

Activity appears concentrated in the upper Midwest, with MMCAP (administered by the Minnesota Department of Administration's Office of State Procurement and serving participating state and local government facilities including Oregon) and Connecticut municipalities posting recent opportunities. The City of Meriden's sodium bisulfite bid (Solicitation B02715, due July 29, 2026) targets the Water Pollution Control Facility and requires General Liability coverage of $1,000,000 to $2,000,000 and performance bonding; pricing evaluation is unit-cost-based. MMCAP's pharmaceutical RFP (Solicitation S1070000015802, proposals due March 26, 2026) establishes multiple contracts for distribution across state and local healthcare facilities, requires cGMP and DSCSA compliance, mandates relationships with at least two of three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), and weights price competitiveness at 75 percent of evaluation. Neither opportunity closely aligns with tocofersolan's intended commodity scope, signaling either misclassification in the posting process or minimal current procurement activity under this specific code.